These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 23532530)
1. Novel oral anti-obesity agents: new perspectives with lorcaserin? Gallwitz B Drugs; 2013 Apr; 73(5):393-5. PubMed ID: 23532530 [No Abstract] [Full Text] [Related]
2. 2 new drugs for weight loss. Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487 [No Abstract] [Full Text] [Related]
3. Lorcaserin: a review of its use in chronic weight management. Hoy SM Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Singh AK; Singh R Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555 [No Abstract] [Full Text] [Related]
5. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. Hurren KM; Dunham MW Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828 [TBL] [Abstract][Full Text] [Related]
6. Multicenter, placebo-controlled trial of lorcaserin for weight management. Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR; N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200 [TBL] [Abstract][Full Text] [Related]
7. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM; J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446 [TBL] [Abstract][Full Text] [Related]
8. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss. Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698 [TBL] [Abstract][Full Text] [Related]
9. New obesity agents: lorcaserin and phentermine/topiramate. Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750 [TBL] [Abstract][Full Text] [Related]
10. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Nigro SC; Luon D; Baker WL Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263 [TBL] [Abstract][Full Text] [Related]
11. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
12. Drug management of obesity--efficacy versus safety. Astrup A N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205 [No Abstract] [Full Text] [Related]
13. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement? Kolotkin RL; Crosby RD; Wang Z Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987 [TBL] [Abstract][Full Text] [Related]
14. What cost weight loss? Hiatt WR; Thomas A; Goldfine AB Circulation; 2012 Mar; 125(9):1171-7. PubMed ID: 22392864 [No Abstract] [Full Text] [Related]
15. Lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy. Hill LG Ann Pharmacother; 2013 Dec; 47(12):1740. PubMed ID: 24396110 [No Abstract] [Full Text] [Related]
16. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity. Valenzuela-Vallejo L; Chrysafi P; Bello-Ramos J; Bsata S; Mantzoros CS Metabolism; 2022 Aug; 133():155237. PubMed ID: 35700837 [TBL] [Abstract][Full Text] [Related]
17. Response to "lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy". Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013 Dec; 47(12):1741. PubMed ID: 24311729 [No Abstract] [Full Text] [Related]